<DOC>
	<DOCNO>NCT01319903</DOCNO>
	<brief_summary>The novel humanized monoclonal antibody CaCP29 develop control inflammatory response various stimulus human espacially sepsis . Purpose phase I clinical trial healthy human male investigate various parameter concern safety tolerability CaCP29 ass pharmacokinetic pharmacodynamic parameter .</brief_summary>
	<brief_title>Clinical Assessment Safety Tolerability New Monoclonal Humanized Antibody CaCP29</brief_title>
	<detailed_description>The acute inflammatory innate host response , present development sepsis various acute inflammatory disease , represent powerful mechanism lead destruction host tissue severe organ dysfunction . CaCP29 develop low complement mediate acute inflammatory response thereby control extend strongly activate often time self-destructive inflammatory response control activation key inflammatory mechanism .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male , Caucasian subject age 1840 year ( inclusive ) Healthy subject determine medical history , physical examination Body weight 70 100 kg BMI 19 29 kg/m2 , extremes incl ECG recording base 12lead ECG normal ( PR &lt; 210 m , QRS &lt; 110 m , QTC 380 430 m ) contain slight deviation Normal vital sign ( 5 minute rest ) , blood pressure value ( systolic &gt; equal 100 &lt; equal 140 mmHg , diastolic &gt; equal 50 &lt; equal 90 mmHg ) , heart rate 45 90 beat per minute ( bpm ) , body temperature &lt; 37.5Â°C Subjects able willing give write informed consent Normal white blood cell count , CRP IL6 screen Day 1 Subjects must use two acceptable method contraception ( e.g . spermicide condom ) study refrain father child 3 month follow dose In opinion investigator subject clinically significant history presence cardiovascular , respiratory , renal , hepatic , metabolic , endocrinological , gastrointestinal , hematological , neurological , dermatological , psychiatric disease , cancer major disease ; Infection known inflammatory process ; Known autoimmune disease immunodeficiency know family history autoimmune diseases immunodeficiency ; Clinical significant allergic disease ; Known serum hepatitis carrier Hepatitis B surface antigen Hepatitis C antibody positive result test HIV 1/2 antibody ; Subjects receive investigational drug and/or vaccination within 3 month prior start treatment study anticipate receipt vaccine within 2 month last dose study drug ; Subjects , receive prior treatment within 1 year monoclonal antibody biologic agent ; The use concomitant prescription nonprescription medication within 14 day prior first administration study medication followup ; treatment medication may affect immune function ( e.g . immunoglobulin , corticosteroid ) within 6 month dose ; Donation blood ( &gt; 400 ml ) blood product within last 3 month prior admission clinical unit plasmapheresis within 4 week prior study start ; Definite suspect personal history adverse reaction hypersensitivity drug especially ingredient trial compound compound similar structure ; Use 5 cup glass coffee , tea / cola per day ; Presence history drug and/or alcohol abuse average daily intake 20 g alcohol per day ; Positive test alcohol drug screen and/or Day 1 ; Smokers &gt; 5 cigarettes/day equivalent ; Subjects unlikely compliant attend schedule clinic visit require ; Participation study previous dose level</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>sepsis</keyword>
	<keyword>inflammation</keyword>
	<keyword>complement</keyword>
	<keyword>immune system</keyword>
</DOC>